Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Date:6/23/2011

BARCELONA, Spain, June 23, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented pre-clinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) decrease pancreatic cancer tumor blood flow and reduce blood vessel density in vivo.  The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, New York.

In a poster presentation, CureFAKtor Senior Scientist Dr. Elena Kurenova reported the antiangiogenic effect of the Company's lead small molecule compound, CFAK-C4, in pancreatic cancer tumors. Contrast-enhanced magnetic resonance imaging (MRI) revealed significant reduction in tumor vascular volume and permeability in CFAK-C4-treated pancreatic tumors in vivo.  MRI-based changes in tumor vascularity were seen at both the first and second week after therapy.

CureFAKtor scientists analyzed the blood vessel density in a subcutaneous mouse pancreatic tumor model in two CFAK-C4 treated groups and compared vessel density to control group tumors treated with phosphate-buffered saline (PBS). One group was treated for 35 days with treatment starting the day after cell injection.  The second treatment group started when tumors reached a volume of 100 cubic millimeters (mm). Tumors from both groups demonstrated statistically significant reduction of blood vessels per square mm equaling blood vessel density.

A CureFAKtor study reported earlier this year pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells.  
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
2. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
3. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
4. Radient Pharmaceuticals Corporation Joins OTCQX
5. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
6. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
7. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
9. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
10. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
11. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
(Date:11/26/2014)... San Luis Obispo, CA (PRWEB) November 26, 2014 ... bunion treatment, is offering lower prices in an early ... November 26th, Bunion Booties are being offered at the ... Black Friday promotional pricing is in addition to any ... Bootie, visit the Bunion Bootie website for ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
(Date:11/26/2014)... The number of emergency department visits in the United States ... 136 million in 2011, according to the U.S. Centers for ... fewer people were going to ERs with non-urgent medical needs: ... within two hours of arriving at the ER. In 2010, ... Sixty percent of patients arrived at the ER after normal ...
Breaking Medicine News(10 mins):Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2
... Neurological Disease have now proved using a specialized mouse ... produced by neurons.// The results of this study have ... the two. ,Also known as apoE, this ... apoE4, is the major known genetic risk factor for ...
... Foundation has found that more than 60 percent of people ... food debris// struck in between their teeth. Items like screwdrivers, ... survey said. ,More disturbingly, the survey said that ... rise to oral health problems and bad breath. "Clearly people ...
... is running short of faculty members and its current strength ... ,Replying to a question, minister of state for health ... running with just 479 faculty members as against its sanctioned ... that during 2003-05, 20 faculty members had either resigned or ...
... and Medicaid Services in Baltimore and George Washington University ... who are depressed resort to nursing homes. Depression among ... of the patient. Hence the researchers analyzed the relationship ... surveyed a total of 141,000 seniors. About 13261 of ...
... Although the new government health refoms have cost millions of pounds ... very little benefit for the patients//. ,Cosultants pay and pension ... state that there is no difference to patient care. ... the hospitals. There has been no planning and no guidance on ...
... but still South Africa's own nursing community is faced ... salute the nurses of South Africa and celebrate those ... lives of others in need," said Siphokazi Phillip, international ... Africa (Denosa). ,According to Philip although there ...
Cached Medicine News:Health News:Alzheimer's-linked apolipoprotein E produced by neurons, Gladstone study 2Health News:Nurses in South Africa Face Challenges 2
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: